细胞色素P4501A1基因多态性和谷胱甘肽硫转移酶基因缺失及烹调油烟暴露与非吸烟女性肺癌易感性的关系

目的 探讨细胞色素P4501 A1(CYP1A1)MspI位点多态性、谷胱甘肽硫转移酶(GSTM1)基因缺失及烹调油烟暴露与非吸烟女性肺癌易感性的关系.方法 2009年3一12月选择中南大学湘雅医院女性非吸烟的原发性肺癌患者及对照各160例,应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)及聚合酶链反应(PCR)技术分别检测CYP1A1 MspI多态性及GSTM1基因型,分析基因的多态性、分型及烹调油烟暴露与肺癌遗传易感性的关系.结果 肺癌组及对照组烹调油烟暴露的频率分别为51.9%(83例)及33.7%(54例),差异有统计学意义(x2=10.734,P＜0.01);肺癌组MspI位点突变的等位基因频率为44.4%(71例),高于对照组(36.9%,59例),差异无统计学意义(X2=3.731,P＞0.05);携带突变型或杂合型基因同时又有油烟暴露个体患肺癌的风险明显增高,OR(odds ratio)值分别为3.032(95%CI为1.291～7.124)和2.769(95%CI为1.341～5.552);肺癌组GSTM1缺失型的频率为58.1%(93例),与对照组(45.0%,72例)比较,差异有统计学意义(X2=0.518,P＜0.05),GSTM1缺失型的个体患肺癌的风险明显增高,OR值为1.697(95%CI为1.090～2.640);携带GSTM1缺失型且有烹调油烟暴露的个体肺癌的易感性明显增加,其OR值为3.617(95%CI为1.899～6.891);GSTM1缺失型与CYP1A1 MspI杂合型或突变型联合作用时,个体患肺癌的风险亦增高,OR值分别为1.966(95%CI为1.007～3.836)和2.402(95%CI为1.023～5.640),差异明显.结论 烹调油烟暴露是非吸烟女性肺癌的危险因素;CYP1A1 MspI基因多态性与烹调油烟联合作用可增加肺癌发病的风险;GSTM1基因缺失可能是非吸烟女性肺癌的遗传易感因素,其与烹调油烟暴露联合作用可明显增加肺癌发病的风险,且GSTM1基因缺失与CYP1A1基因多态性存在交互作用.     

CYP2E1,GSTM1基因多态性与甘肃地区食管癌易感性

目的探讨细胞色素氧化酶P450,GSTM1的基因多态性与甘肃地区食管癌遗传易感性之间的以及基因—基因的交互作用。方法运用病例对照分子流行病学研究方法和聚合酶链反应方法对食管癌病例组和正常对照组基因DNA进行CYP2E1,GSTM1基因分型。结果CYP2E1基因pst1多态性的三种基因型在食管癌组和对照组的频率差异有统计学意义（χ2=12.59,P〈0.05）。携带C1/C1基因型个体发生食管癌的风险是携带其他基因型2.80倍（OR=2.80,95%C I=1.21-6.46）。食管癌组GSTM1（-）基因型频率显著高于对照组（χ2=10.292,P〈0.05）,携带GSTM1（-）的个体患食管癌的危险性显著高于GSTM1（＋）基因型的个体（OR=2.337,95%C I=1.39-3.93）。联合分析CYP2E1基因pst1多态性和GSTM1基因多态性,携带有C1/C1和GSTM1（-）基因型的个体患食管癌的风险高于携带GSTM1（＋）和C1/C2或C2/C2基因型的个体（OR=3.00,95%C I=1.7375-5.182）。结论CYP2E1,GSTM1基因多态性与食管癌易感性有关联,CYP2E1基因C1/C1基因型是食管癌的易感性基因,而GSTM1基因缺失使食管癌危险性增加,CYP2E1,GSTM1存在交互作用。     

CYP1A1基因多态性和吸烟对肺癌的易感性

目的采用PCR-RFLP技术测定CYP1A1的mspI和exon 7位点多态性,并观察两者及吸烟对肺癌易感性的影响。方法研究采用等位基因特异性扩增和PCR-RFLP技术,分析CYP1A1基因3'端限制性内切酶mspI和exon 7位点基因的基因多态性。结果 CYP1A1的mspI和exon 7位点各自基因型分布频率均无显著性差异(χ2=1.34,P>0.05);其中mspI突变型TC和CC患肺癌的相对危险性增加(OR=1.18,P<0.05;OR=1.49,P<0.05);exon 7突变型Ile/Val和Val/Val患肺癌的相对危险性亦增加(OR=1.35,P<0.05;OR=2.70,P<0.05);两多态位点联合作用分析,表明携带突变基因的个体肺癌易感性较高(OR=4.42,P<0.05)。对肺癌易感性与吸烟的关系分析,吸烟者患肺癌的危险性是不吸烟者1.77倍(χ2=5.72,P<0.05);携带突变基因且吸烟者肺癌易感性显著增加(OR=2.16,P<0.05;OR=2.63,P<0.05)。结论 CYP1A1突变型基因可能增加肺癌的易感性;CYP1A1突变型基因与吸烟之间存在协同作用,明显提高了患肺癌的风险性。     

CYP1A1及GSTM1基因多态性对肺癌发病的影响

目的探讨代谢活化酶细胞色素P4501A1（CYP1A1）及谷胱甘肽硫转移酶M1（GSTM1）基因多态性和环境暴露与肺癌易感性的关系。方法用聚合酶链反应—限制性片段长度多态性技术测定158例肺癌患者和455例对照者的CYP1A1及GSTM1基因多态性。结果与对照组比较，肺癌组吸烟、粉尘接触频率明显升高，而摄入蔬菜水果及消毒水频率明显降低（P均〈0．01）；两组CYP1A1与GSTM1基因各类型分布无统计学差异；CYP1A1突变型基因及GSTM1缺陷型与吸烟有协同致肺癌作用。结论吸烟、接触粉尘均增加肺癌发生率，而摄入蔬菜水果及消毒水降低其危险性；吸烟可增加CYP1A1基因突变型或GSTM1基因缺陷型个体肺癌发生的危险性。     

谷胱甘肽转硫酶T1、M1和P1基因多态与反流性食管炎易感性

目的　研究谷胱甘肽转硫酶 (GSTs)T1、M1和P1基因多态与反流性食管炎易感性的关系。方法　采用病例 对照分子流行病学研究方法 ,以多重PCR技术检测GSTT1和GSTM 1基因缺失 ,以PCR RFLP技术检测GSTP1基因单核苷酸多态 (第 10 4密码子A→G)。结果　共检测了 10 9例反流性食管炎患者、97例有胃食管反流症状但胃镜检查阴性 (NERD)的患者和 97例正常对照者。GSTT1和GSTM 1基因缺失频率在食管炎组、NERD组和正常组分别为 48.6 %、42 .6 %、5 3 .6 %和 5 2 .0 %、5 3 .6 %、43 .3% ,差异无显著性。然而 ,反流性食管炎组突变型GSTP1(40 .4% )基因频率显著高于NERD组 (2 4.7% ,P <0 .0 5 )和正常对照组 (2 1.6 % ,P <0 .0 5 )。携带GSTP1变异基因型者比携带野生型基因型者发生反流性食管炎的风险高 2 .42倍 (95 %CI ,1.2 2～ 4.80 )。在携带GSTP1变异基因型同时无幽门螺杆菌感染的个体 ,食管炎的OR值则增加到 2 .6 7(95 %CI 1.0 6～ 6 .70 )。结论　GSTP1基因 (10 4密码子A→G)多态可能是涉及反流性食管炎发生的遗传易感因素。幽门螺杆菌感染可能会降低反流性食管炎的发生 ,它可能是反流性食管炎的保护因素。     

细胞色素CYP2A6基因多态性与COPD易感性的关系

目的探讨细胞色素CYP2A6基因多态性与COPD易感性的关系。方法应用聚合酶链反应-限制性片段长度多态性法(PCR-RFLP)检测40例COPD患者及37例健康体检者静脉血细胞色素P450 2A6位点等位基因和基因型。结果 1.COPD患者CYP2A6-163C>A位点基因缺失型(del)和野生型(wt)基因型频率为17.5%、82.5%,健康对照组分别为40.5%、59.5%,两组基因分布频率差异有统计学意义(χ2=5.000,P=0.025),携带CYP2A6wt基因型者较携带CYP2A6del基因型者患COPD风险增加(OR=0.31,95%CI=0.109-0.886,P<0.05)。2.在吸烟者中,携带CYP2A6wt基因型者较携带CYP2A6del基因型者患COPD风险增加(OR=0.24,95%CI=0.064-0.920,P<0.05),在不吸烟者中,携带CYP2A6wt、CYP2A6del基因型者之间患COPD风险无明显差异。结论 1.CYP2A6-163C>A基因多态性可能是COPD发病的危险因素。2.野生型(wt)可能为吸烟者患COPD的一个易感因素。     

谷胱甘肽S-转移酶M1、T1基因多态性与骨肉瘤易感性的Meta分析

目的 定量分析谷胱甘肽S-转移酶M1、T1(GSTM1、GSTT1)基因多态性与骨肉瘤易感性的关系.方法 检索PubMed、Embase、CNKI、维普、万方数据平台从建库到2013年2月的文献,对符合本实验纳入标准和排除标准的随机对照临床研究,运用RevMan5.0.0软件进行Meta分析.结果 共纳入3篇文献,累计样本量为914例,其中病例组202例,对照组712例.Meta分析见GSTTI位点的多态性与骨肉瘤易感性有显著关联,而GSTM1和骨肉瘤无显著关联(基因型GSTM1空白对GSTM1非空白:OR=1.21,95％ CI:0.86～1.70,P=0.27;基因型GSTT1空白对GSTT1非空白:OR=1.58,95％ CI:1.11 ～2.25,P=0.01).结论 GSTT1基因多态性与骨肉瘤相关,GSTT1空白基因型可能增加骨肉瘤的发病.     

ⅠⅡ相代谢酶基因多态性与食管癌遗传易感性的病例对照研究

目的研究细胞色素P450（CYP）1A1和谷胱甘肽转硫酶M1（GSTM1）和T1（CSlTrl）基因多态性与食管癌易感性的关系。方法应用PCR—RFLP技术对87例食管癌患者和162例无上消化道肿瘤的健康者的CYP1A1、GSTMl和GSlTrl的基因多态性进行分析。比较两组基因型频率的差异。结果食管癌组CYPlAlIle—Val多态位点各等位基因和基因频率与对照组比较，差别有统计学意义，其中Val／Val基因型在食管癌组的频率（29．9％）显著高于对照组（13．0％）（X^2=10．54，P〈0．01），OR值为3．10，95％CI为（1.57，6．14），而CYPlAl的Ⅱe／Val、Ⅱe／Ⅱe多态位点和GSTMl与GSTTl的缺失多态性的基因型频率与对照组比较，差别无统计学意义（P〉0．05）。结论CYPlAlVal／Val基因型为食管癌的重要易感因素之一，而GSTMl与GSTTl的基因型可能与食管癌的发生无关。     

细胞色素P450亚型基因多态性分析及对华法林用药剂量的影响

目的探讨细胞色素P450亚型(CYP2C9)基因多态性与华法林抗凝治疗维持剂量的相关性。方法选择服用华法林的汉族患者200例,男性和女性各100例。患者均为心脏瓣膜置换术后。通过CAPS技术及常规DNA测序方法对CYP2C9基因的3个候选位点(CYP2C9*2、CYP2C9*3、CYP2C9*c65)进行测定。并分析携带不同基因患者华法林应用剂量差异。结果 200例患者中,并未检测到CYP2C9*2位点发生突变,仅检测到1种等位基因C,基因型全部为C/C野生型。检测到CYP2C9*3A和C位点,其中A/A野生型为171例,占85.5%;A/C杂合子突变型为18例,占9.0%;C/C纯合子突变型为11例,占5.5%。等位基因A频率为94.3%,等位基因C频率为5.7%。CYP2C9*3基因突变与服用华法林剂量存在显著差异(P0.05),A/C型患者服药剂量较A/A型患者降低了18.5%,C/C型患者服药剂量较A/A型降低了76.0%。CYP2C9*c65位点检测出G和C位点2种等位基因,G/G野生型182例,占91.0%;G/C杂合子突变型为18例,占9.0%;这2种基因突变患者的华法林维持剂量之间不存在明显相关性。结论 CYP2C9基因多态性与华法林抗凝治疗维持剂量有一定相关性。     

哈萨克族食管癌与CYP2E1基因多态性及烟酒嗜好的关系

目的:探讨细胞色素P4502E1(CYP2E1)基因多态性,烟酒嗜好与哈萨克族食管癌易感性的关系.方法:采用1:2配比的病例对照研究方法,调查哈萨克族食管癌患者120例和非食管癌患者240例,采用聚合酶链-限制性片段长度多态(PCR-RFLP)方法检测CYP2E1 RsaⅠ位点的基因型.结果:病例组中CYP2E1 RsaⅠ位点C1/C1、C1/C2、C2/C2基因型频率与对照组比较(78.3%vs53.3%,19.2%vs 37.5%,2.5%vs 9.2%,X~2=21.794,P<0.01)差异有统计学意义:携带C1/C1基因型发生食管癌的危险性是携带C1/C2或C2/C2基因型的3.07倍(95%CI:1.87.5.03);交互作用提示CYP2E1基因多态与吸烟、饮酒均存在交互作用;其危险性远高于各单独作用之和.结论:CYP2E1 RsaⅠ位点基因多态性与大量吸烟、饮酒之间的基因-环境交互作用可增强哈萨克族人群患食管癌的风险.     

CYP1A1 , GSTM1 , GSTT1 and NQO1 polymorphisms and colorectal adenomas in Japanese men

AIM: To investigate the role of functional genetic poly-morphisms of metabolic enzymes of tobacco carcinogens in the development of colorectal adenomas. METHODS: The study subjects were 455 patients with colorectal adenomas and 1052 controls with no polyps who underwent total colonoscopy in a preretirement health examination at two Self Defense Forces hospitals. The genetic polymorphisms studied wereCYP1A1*2A (rs 4646903), CYP1A1*2C (rs 1048943), GSTM1 (null or non-null genotype), GSTT1 (null or non-null genotype) and NQO1 C609T (rs 1800566). Genotypes were determined by the polymerase chain reaction (PCR)-restriction fragment length polymorphism or PCR method using genomic DNA extracted from the buffy coat. Cigarette smoking and other life-style factors were ascertained by a self-administered questionnaire. The associations of the polymorphisms with colorectal adenomas were examined by means of OR and 95%CI, which were derived from logistic regression analysis. Statistical adjustment was made for smoking, alcohol use, body mass index and other factors. The gene-gene interaction and effect modification of smoking were evaluated by the likelihood ratio test. RESULTS: None of the five polymorphisms showed a significant association with colorectal adenomas, nor was the combination of GSTM1 and GSTT1 . A borderline significant interaction was observed for the combination of CYP1A1*2C and NQO1 (P = 0.051). The OR associated with CYP1A1*2C was significantly lower than unity among individuals with the NQO1 609CC genotype. The adjusted OR for the combination of the CYP1A1*2C allele and NQO1 609CC genotype was 0.61 (95%CI: 0.42-0.91). Although the interaction was not statistically significant (P = 0.24), the OR for individuals carrying the CYP1A1*2C allele and GSTT1 null genotype decreased significantly compared with those who had neither CYP1A1*2C allele nor GSTT1 null genotype (adjusted OR: 0.69, 95%CI: 0.49-0.97). Smoking did not modify the associations of the individual polymorphisms with colorectal adenomas. There w     

Cytochrome 1A1 and 1B1 gene diversity in the Zanzibar islands

Amodiaquine (AQ) is a 4‐aminoquinoline widely used in the treatment of malaria as part of the artemisinin combination therapy (ACT). AQ is metabolised towards its main metabolite desethylamodiaquine mainly by cytochrome P450 2C8 (CYP2C8). CYP1A1 and CYP1B1 play a minor role in the metabolism but they seem to be significantly involved in the formation of the short‐lived quinine‐imine. To complete the genetic variation picture of the main genes involved in AQ metabolism in the Zanzibar population, previously characterised for CYP2C8, we analysed in this study CYP1A1 and CYP1B1 main genetic polymorphisms. The results obtained show a low frequency of the CYP1A1*2B/C allele (2.4%) and a high frequency of CYP1B1*6 (approximately 42%) followed by CYP1B1*2 (approximately 27%) in Zanzibar islands. Genotype data for CYP1A1 and CYP1B1 show a low incidence of fast metabolisers, revealing a relatively safe genetic background in Zanzibar’s population regarding the appearance of adverse effects.     

Interleukin-1 and interleukin-1 antagonism.

The polypeptide cytokine interleukin-1 (IL-1) affects nearly every tissue and organ system. IL-1 is the prototype of the pro-inflammatory cytokines in that it induces the expression of a variety of genes and the synthesis of several proteins that, in turn, induce acute and chronic inflammatory changes. IL-1 is also the prototypic "alarm" cytokine in that it brings about increases in a variety of defense mechanisms, particularly immunologic and hematologic responses. Most studies on the biology of IL-1 have been performed in animals, but human subjects have recently been injected with recombinant IL-1 and the results confirm the two fundamental properties of IL-1 as being both a mediator of disease as well as of host defense. However, in either situation, over or continued production of IL-1 leads to debilitation of normal host functions; therefore, reduction of IL-1 synthesis or its effects becomes a target of therapy in many diseases. In this review, the structure, gene expression, synthesis, and secretion of IL-1 are described. In addition, the two IL-1 surface receptors, possible signal transduction mechanisms, various biologic activities, and production of IL-1 during disease states are discussed. Similarities and differences between IL-1, tumor necrosis factor, and IL-6 are presented. Although various agents for reducing the synthesis and/or for antagonizing the effects of IL-1 have been proposed, the recent cloning of a naturally occurring IL-1 receptor antagonist (IL-1ra) has opened new experimental and clinical approaches. The ability of this IL-1ra to block the triggering of IL-1 receptors in animals without agonist effects has reduced the severity of diseases such as hemodynamic shock, lethal sepsis, inflammatory bowel disease, experimental arthritis, and the spontaneous proliferation of human leukemic cells.     

1-Naphthyl isocyanate and 1-naphthylamine as metabolites of 1-naphthylisothiocyanate

Abstract: The importance of the bioactivation of 1-naphthylisothiocyanate was studied. Forty minutes after 1-naphthylisothiocyanate administration to rats, bile was collected over a 2.5-h period; the liver was then excised and homogenized. 1-naphthylisothiocyanate and its metabolites in bile and liver of rats were identified and quantified using coupled gas chromatography-mass spectrometry. Three main compounds were found in all 1-naphthylisothiocyanate-treated animals. They were identified as 1-naphthyl isocyanate, 1-naphthylamine and the parent compound, 1-naphthylisothiocyanate. When rats were given cycloheximide, which attenuates 1-naphthylisothiocyanate toxicity, 30 min before 1-naphthylisothiocyanate (300 mg/kg), 1-naphthyl isocyanate concentration was significantly lower than in rats receiving only 1-naphthylisothiocyanate. The appearance of 1-naphthylamine was also inhibited by cycloheximide, although not to the same extent as 1-naphthyl isocyanate. On the other hand, phenobarbital, which potentiates 1-naphthylisothiocyanate hepatotoxicity, enhanced 1-naphthyl isocyanate and 1-naphthylamine formation. It is suggested that 1-naphthyl isocyanate, 1-naphthylamine and the highly reactive sulfur released from 1-naphthylisothiocyanate might be involved in the hepatotoxic effect of 1-naphthylisothiocyanate.     

Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis

Cooperative activation of Meis1 and Hoxa9 perturbs myeloid differentiation and eventually leads myeloid progenitors to leukemia, yet it remains to be clarified what kinds of subsequent molecular processes are required for development of overt leukemia. To understand the molecular pathway in Hoxa9/Meis1-induced leukemogenesis, retroviral insertional mutagenesis was applied using retrovirus-mediated gene transfer. The mice that received Hoxa9/Meis1-transduced bone marrow cells developed acute myeloid leukemia (AML), and Trib1, Evi1, Ahi1, Raralpha, Pitpnb, and AK039950 were identified as candidate cooperative genes located near common retroviral integration sites. Trib1 and Evi1 were up-regulated due to retroviral insertions, and coexpression of these genes significantly accelerated the onset of Hoxa9/Meis1-induced AML, suggesting that Trib1 and Evi1 are the key collaborators. Furthermore, Trib1 by itself is a novel myeloid oncogene, enhancing phosphorylation of ERK, resulting in inhibition of apoptosis. These results demonstrate the importance of specific oncogene interaction in myeloid leukemogenesis.     

甲型H1N1与季节性H1N1流感病毒血凝素基因比较分析

目的分析泰安市2008～2009年度季节性流感与2009年度甲型H1N1流感病原学检测结果 ,比较季节性H1N1与甲型H1N1血凝素基因变异情况。方法选择国家级流感监测哨点医院以及暴发疫情的疫点,采集流感样病例的鼻咽拭子标本,通过RealtimePCR进行病毒检测,用MDCK细胞进行病毒分离,通过RT-PCR扩增血凝素HA1片段的基因并测序,利用生物信息学进行序列分析。结果 2008～2009年共检测鼻咽拭子标本283份,分离出流感病毒33株,分离阳性率为11.67%,其中季节性H1N1亚型31株。2009年5月1日～12月31日,检测鼻咽拭子标本996份,流感核酸检测阳性417份,阳性率为41.86%,其中甲型H1N1337份,季节性H1N1亚型1份。6株季节性H1N1病毒均在多个氨基酸位点上发生变异,与疫苗株A/Brisbane/59/2007(H1N1)比较,有11个位点发生了突变,其中5个位点位于抗原决定簇上;测序成功的6株甲型H1N1病毒在多个氨基酸位点发生变异,与疫苗株A/California/07/2009(H1N1)比较,有6个位点发生突变,其中1个位点位于抗原决定簇的B区。结论 2008～2009年度季节性H1N1为优势株,甲流暴发后,甲型H1N1成为绝对优势毒株。季节性H1N1分离株有多处氨基酸替换,抗原决定簇B区变异频繁;甲型H1N1病毒分离株的基因有变异,但关键位点第222位仍为D(天冬氨酸),与疫苗株相比抗原决定簇的关键位点变化不大。     

GSTT1, GSTM1 and GSTP1 polymorphisms and susceptibility to juvenile idiopathic arthritis

OBJECTIVE: In this study we have analyzed GSTM1, GSTT1 and GSTP1 polymorphisms in patients with juvenile idiopathic arthritis (JIA), to investigate a possible role of these genes as genetic components of the disease. METHODS: A total of 103 individuals (49 oligoarticular, 41 polyarticular and 13 systemic) were analyzed for the three polymorphisms, using a PCR/RFLP methodology. RESULTS: We have observed significantly increased frequencies of individuals with GSTT1 null genotype in JIA patients comparing to controls (37% x 21%; p=0.0183). There was a 2-fold increased risk (OR 2.2, 95% CI 1.2-4.1) associating the disease with the GSTT1 null genotype. Considering the subgroups (oligoarticular, polyarticular and systemic), the results indicated an association between polyarticular and systemic patients and the GSTT1 null genotype. There was a 2-fold increased risk for polyarticular patients (OR 2.4, 95%, CI 1.1-5.4), and a 4-fold increased risk for systemic patients (OR 4.4, 95%, 1.3-14.5). CONCLUSION: The GSTT1 null genotype seems to be involved in polyarticular and systemic JIA.     

Glutathione S-transferase M1, T1, and P1 genotypes and rheumatoid arthritis

OBJECTIVE: To determine the effects of genetic polymorphisms of glutathione S-transferase (GST) M1, GSTT1, and GSTP on risk and severity of rheumatoid arthritis (RA) in a Korean population. METHODS: A total of 258 patients with RA and 400 disease-free controls were enrolled. GST genotypes were determined by RFLP-PCR. HLA-DRB 1 typing and further subtyping of all alleles was performed using sequence-specific oligonucleotide probe hybridization after PCR. Severity of RA among cases was assessed by Steinbrocker anatomical stage. Risk was assessed by calculating the age and sex adjusted odds ratio (OR) and 95% confidence intervals (CI). RESULTS: The OR for risk of RA with the GSTM1-null genotype was 1.40 (95% CI 1.02- 1.92, p = 0.04), and 1.86 (95% CI 1.12- 3.09, p = 0.005) among individuals without the shared epitope (SE). Among patients with RA, the OR for risk of severe RA for the GSTM1-null genotype was 2.45 (95% CI 1.04- 5.77, p = 0.02). No association was observed between the GSTT1 or GSTP1 genotypes and either risk or severity of RA. CONCLUSION: These results suggest that the deletion polymorphism of GSTM1 is associated with increased susceptibility for RA, particularly among individuals who are not carriers of the HLA-DRB 1 SE.